Glioblastoma is a aggressive brain cancer known for its fast growth and resistance to standard treatments. Investigations are constantly underway to identify new management strategies, and recently, a new biomarker named LCA168 has emerged as a potential avenue for glioblastoma treatment. LCA168 is a protein that is abundantly produced in GBM cell